Vivos Therapeutics

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Highlands Ranch, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q3 2022

Earnings data Q2 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vivos Therapeutics reports revenue decline but eyes growth through FDA clearances

Vivos Therapeutics reported a decline in revenue for Q1 2024 but showcased improved operating performance and cash flow management. The company is focused on revenue growth initiatives, strategic collaborations, and expanding product access to achieve cash flow positivity by late 2024 or early 2025. Challenges include revenue decline and the need to reduce dependency on dentistry channel.

Vivos Therapeutics reports robust Q2 earnings, eyes market expansion

Vivos Therapeutics delivered a strong Q2 2024 performance with revenue growth, improved margins, and cost management driving financial stability and operational efficiency.
The company's strategic initiatives, including the alliance with a sleep clinic and FDA clearances, position it well for market expansion and revenue enhancement.
While challenges in maintaining growth and managing costs persist, Vivos has opportunities to leverage its strengths in customer loyalty, financial stability, and market reach for sustainable growth.
By focusing on revenue optimization, cost control, and strategic partnerships, Vivos aims to enhance profitability, drive innovation, and capture new market opportunities.

Vivos Therapeutics reports revenue growth and strategic expansion plans

Vivos Therapeutics showed revenue growth and improved gross profit margins in Q3 2024. Despite challenges in net loss and cash burn, the company is optimistic about achieving positive cash flow and expanding its market presence through strategic alliances.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Littleton, CO.

First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults

Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement

Vivos Therapeutics (NASDAQ:VVOS) is on track to become cash flow positive by the end of 2024, its CEO revealed in its latest financial update. “Based on our progress to date and our revenue growth efforts for 2024, we continue to anticipate becoming cash flow positive from operations by the end of this year,” CEO Kirk Huntsman told shareholders.

Vivos Therapeutics highlights path to cash flow positivity after FDA clearance

Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript

Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos' Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults)), today announced it plans to release its fourth quarter and full year 2023 financial results after market close today, Thursday, March 28, 2024.

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Vivos Therapeutics (NASDAQ:VVOS) announced that it has entered into a definitive agreement to immediately exercise an outstanding stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares for approximate proceeds of $4 million. The net proceeds will be used by the medical device company specializing in treatments for sleep-related breathing disorders for general corporate purposes.

Vivos Therapeutics sees gross proceeds of $4M from exercise of warrant

Vivos Therapeutics (NASDAQ:VVOS) is well-positioned to increase the adoption of its oral medical devices for the treatment of severe obstructive sleep apnea as patients seek alternatives to continuous positive airway pressure (CPAP).  The company's Vivos CARE oral appliance in November 2023 received US Food and Drug Administration (FDA) approval to treat moderate to severe obstructive sleep apnea in adults along with positive airway pressure and/or myofunctional therapy, as required.

Vivos Therapeutics sees opportunities for its FDA-approved oral sleep apnea treatment amid CPAP market disruptions

Vivos Therapeutics (NASDAQ:VVOS) sees significant new opportunities for its oral appliances targeting patients with sleep-related breathing disorders including obstructive sleep apnea (OSA) amid recent market developments. The company's Vivos CARE appliances in November 2023 were cleared by the US Food and Drug Administration (FDA) to treat moderate and severe OSA in adults along with positive airway pressure and/or myofunctional therapy as required, making them the only oral appliance to win FDA approval to treat severe OSA.

Vivos Therapeutics sees revenue opportunities for its oral devices from recent market developments

United Healthcare Updated Medical Policy Favoring Oral Appliance Therapies and Recent Recalls of Many ResMed and Philips Respironics' CPAP Devices Create Significant Revenue Opportunities for Vivos Devices United Healthcare Updated Medical Policy Favoring Oral Appliance Therapies and Recent Recalls of Many ResMed and Philips Respironics' CPAP Devices Create Significant Revenue Opportunities for Vivos Devices

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Vivos Therapeutics (NASDAQ:VVOS) told investors it has experienced a surge in interest in the wake of the FDA 510(k) clearance from the US Food and Drug Administration (FDA) for its CARE (Complete Airway Repositioning and/or Expansion) oral medical devices targeting severe obstructive sleep apnea (OSA). The medical technology firm said the groundbreaking clearance, granted on November 28, 2023, marks the first time the FDA has approved an oral appliance for treating moderate and severe OSA in adults, aged 18 and older, complemented by positive airway pressure (PAP) and/or myofunctional therapy.

Vivos Therapeutics reports surge in interest following FDA clearance for oral device treatment of sleep apnea

New Dentist Inquiries Jumped 600% and Signed Dentist Enrollment Contracts up 38% Sequentially Over Q3 CARE Oral Medical Device Unit Orders Increased 26% Following FDA Clearance LITTLETON, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA)), is pleased to announce that Vivos is seeing positive preliminary metrics following its November 28, 2023 announcement regarding FDA 510(k) clearance of its CARE oral medical devices to treat severe OSA.

Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

Vivos Therapeutics (NASDAQ:VVOS) announced that it will be hosting a women-led airway health-focused event at the Vivos Institute in Denver, Colorado, on February 1 and 2, 2024. The company said the event, “Empowering Women to Champion Airway,” will bring together prominent women in the medical and dental fields to drive collaboration around airway health.

Vivos Therapeutics announces women-led airway health event

Vivos unites influential women leaders in medicine and dentistry to drive collaboration following first ever FDA 510(k) clearance of an oral device to treat severe OSA Vivos unites influential women leaders in medicine and dentistry to drive collaboration following first ever FDA 510(k) clearance of an oral device to treat severe OSA

Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”

Every so often, a move occurs in the stock market that can best be described as a 'black swan.' That is to say, a move that occurs in an individual stock that is exceedingly rare from a probabilistic standpoint.

Black Swan: this small cap surged over 1000% last week

Vivos Therapeutics (NASDAQ:VVOS) Inc's recently announced FDA clearance for its oral appliances to treat severe obstructive sleep apnea (OSA) has sparked much investor interest, sending its stock price soaring more than 800% in a single trading session.  Vivos CEO Kirk Huntsman spoke with Proactive following the announcement to explain the significance of this milestone and why it could be so transformative for the company.

Vivos Therapeutics severe sleep apnea treatment's a ‘breakthrough', says CEO

Vivos Therapeutics (NASDAQ: VVOS ) stock is falling on Thursday after the medical technology company's shares underwent a massive rally on Wednesday. During normal trading hours yesterday, shares of VVOS stock rallied 831.8% higher.

Why Is Vivos Therapeutics (VVOS) Stock Down 35% Today?

What a day it's been for Vivos Therapeutics (NASDAQ:VVOS). The medical technology company saw its shares shoot over 800% higher on Wednesday after news broke that it had received 510(k) clearance from the US Food and Drug Administration (FDA) for its removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances to treat severe obstructive sleep apnea (OSA) in adults.

Vivos Therapeutics: Who is the medical device company creating frenzy in the markets?

Vivos Therapeutics (NASDAQ: VVOS ) stock is rocketing higher on Wednesday after the Food and Drug Administration (FDA) granted approval to its sleep apnea treatment device. According to a press release from the company, it has been granted 510(k) clearance from the FDA for its removable CARE oral applications.

Why Is Vivos Therapeutics (VVOS) Stock Up 290% Today?

Vivos Therapeutics Inc. shares VVOS jumped more than 270% Wednesday after the medical-device maker got regulatory clearance for removable oral appliances that treat obstructive sleep apnea.

Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance

Vivos Therapeutics (NASDAQ:VVOS) announced that it has been granted 510(k) clearance from the US Food and Drug Administration (FDA) for treating severe obstructive sleep apnea (OSA) in adults using the Vivos' removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances.    The medical technology firm said with the unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new revenue opportunities for the company.

Vivos Therapeutics receives first ever FDA 510(k) clearance for oral device treatment of sleep apnea

Vivos Therapeutics said on Wednesday the U.S. health regulator has cleared its oral device treatment for severe obstructive sleep apnea (OSA).

US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea

With this unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new revenue opportunities for Vivos With this unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new revenue opportunities for Vivos

Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q3 2023 Earnings Conference Call November 14, 2023 5:00 PM ET Company Participants Julie Gannon - Investor Relations Officer Kirk Huntsman - Chairman and Chief Executive Officer Brad Amman - Chief Financial Officer Conference Call Participants Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone, and welcome to the Vivos Therapeutics Third Quarter 2023 Earnings Conference Call. At this time, participants are in a listen-only mode.

Vivos Therapeutics, Inc. (VVOS) Q3 2023 Earnings Call Transcript

Vivos Therapeutics (NASDAQ:VVOS) reported third-quarter results after the bell Tuesday, highlighting cost-cutting initiatives that CEO Kirk Huntsman says have positioned the company well moving forward.  The medical technology company slashed operating expenses by 32% year-over-year and its net loss by 61%.

Vivos Therapeutics showcases the impact of its cost-cutting initiatives with 3Q results

Operating Expenses Decreased 32% Year Over Year and 19% Sequentially as Cost Cutting Measures Take Hold New Strategic Relationships, Including U.S. Nationwide Distribution Agreement with Lincare, Expected to Add Potentially Significant New Revenue Opportunities Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, today reported financial results and operating highlights for the third quarter and nine months ended September 30, 2023.

News for Vivos Therapeutics Stock (VVOS)